EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Personalized care of paediatric drug‐resistant epilepsy in Africa: A single‐centre pilot study utilizing mobile health and genetic testing

Ian S Olivier iD, Karen Fieggen, Sandra Komarzynski, Elin H Davies, Irene Muchada, Caitlin McIntosh, Alina Esterhuizen, Richard J Burman iD, Jo M Wilmshurst iD, University of Cape Town (UCT) Human Genetics Precision Medicine Epilepsy Group

Developmental Medicine & Child Neurology · 2026

DOI: 10.1111/dmcn.16478 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Developmental Medicine & Child Neurology, 2026. Verfasst von Ian S Olivier und 9 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Institute, University of Cape Town, Cape Town, South Africa. Hauptthemen laut MEDLINE: Telemedicine, Precision Medicine, Drug Resistant Epilepsy, Genetic Testing. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Newton Fund, South African Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To evaluate personalized care or precision medicine initiatives, including mobile health (mHealth) technology and genetic screening, in a South African paediatric epilepsy clinic.

Method

This exploratory prospective observational pilot study included 39 children aged 4 years or older with drug‐resistant epilepsy (ongoing seizures despite at least two antiseizure medications at adequate doses). Participants were recruited from the epilepsy service at the Red Cross War Memorial Children's Hospital in Cape Town, the largest paediatric hospital in sub‐Saharan Africa. mHealth technology – a wearable device and mobile application – allowed recording of seizures, medication, sleep, mobility, quality of life, and health visits. Genetic testing included a customized gene panel and pharmacogenomic arrays.

Results

Seizure frequency, but not duration, was significantly greater in clinical records before and during the study period (8.0 and 5.5 median seizures per month respectively) compared with mHealth records of 2.0 median seizures per month ( n = 28, p < 0.001, r = 0.64, 95% confidence interval [CI] 2.62–14.25, Wilcoxon signed‐rank test, and n = 21, p < 0.001, r = 0.76, 95% CI 2.25–15.75, Wilcoxon signed‐rank test respectively). Wearable devices detected decreased activity and sleep in patients compared with age‐matched typically developing peers (both p < 0.001, Mann–Whitney U test). Structural abnormalities were the most common aetiology. Pathogenic variants occurred in two different probands in SCN1A , one likely pathogenic variant in GRIN2A , and two variants of unknown significance in GABRG2 and GRIN2B . Pharmacogenomic analyses identified variants of interest in CYP2D6 , EPHX1 , and SCN1A .

Interpretation

Precision medicine for drug‐resistant epilepsy using mHealth and genetics may show use in a resource‐limited setting. This study, the first demonstration of precision medicine in an African paediatric setting, informs the development of diagnostic testing and provides novel insights into the lives and genetics of affected children.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TelemedicinePrecision MedicineDrug Resistant EpilepsyGenetic TestingHumansPilot ProjectsMaleChildFemaleChild, PreschoolAdolescentSouth AfricaProspective StudiesAnticonvulsants

Substanzen

Anticonvulsants

Autor:innen und Institutionen

  • Neuroscience Institute, University of Cape Town, Cape Town, South Africa.
  • Department of Psychiatry and Mental Health, University of Cape Town, Observatory, South Africa.
  • Division of Human Genetics, Department of Medicine, University of Cape Town, Observatory, South Africa.
  • Aparito Ltd, Wrexham, UK.
  • National Health Laboratory Service, Groote Schuur Hospital, Cape Town, South Africa.
  • Department of Paediatric Neurology, Red Cross War Memorial Children's Hospital, Cape Town, South Africa.

ORCID-Profile: Ian S Olivier, Richard J Burman, Jo M Wilmshurst

Förderung

  • Newton Fund
  • South African Medical Research Council

Zitieren

APA

Olivier, I. S., Fieggen, K., Komarzynski, S., Davies, E. H., Muchada, I., McIntosh, C., Esterhuizen, A., Burman, R. J., Wilmshurst, J. M., & University of Cape Town (UCT) Human Genetics Precision Medicine Epilepsy Group (2026). Personalized care of paediatric drug‐resistant epilepsy in Africa: A single‐centre pilot study utilizing mobile health and genetic testing. Developmental Medicine & Child Neurology. https://doi.org/10.1111/dmcn.16478

Vancouver

Olivier IS, Fieggen K, Komarzynski S, Davies EH, Muchada I, McIntosh C, et al. Personalized care of paediatric drug‐resistant epilepsy in Africa: A single‐centre pilot study utilizing mobile health and genetic testing. Developmental Medicine & Child Neurology. 2026. doi:10.1111/dmcn.16478

BibTeX
@article{Olivier2026,
  author = {Olivier, Ian S and Fieggen, Karen and Komarzynski, Sandra and Davies, Elin H and Muchada, Irene and McIntosh, Caitlin and Esterhuizen, Alina and Burman, Richard J and Wilmshurst, Jo M and University of Cape Town (UCT) Human Genetics Precision Medicine Epilepsy Group, University of Cape Town (UCT) Human Genetics Precision Medicine Epilepsy Group},
  title = {Personalized care of paediatric drug‐resistant epilepsy in Africa: A single‐centre pilot study utilizing mobile health and genetic testing},
  journal = {Developmental Medicine & Child Neurology},
  year = {2026},
  doi = {10.1111/dmcn.16478}
}
Kostenlos starten →